Table 1:
Literature review: Cases of CNS LYG.
|
Case |
Age |
Gender |
LYG grade |
CNS only |
Surgery |
ChemoTx |
RT |
Steroid only |
Ritux |
F/U (m/o) |
Best response |
Time to progression |
Survival (m/o) |
Ref |
|
1 |
63 |
M |
1 |
No |
No data |
CVP |
No |
No |
Yes |
65 |
No data |
No data |
Not reached |
[3] |
|
2 |
72 |
M |
1 |
No |
No data |
No |
Yes |
No |
No |
53 |
CR |
50 |
Not reached |
[3] |
|
3 |
54 |
M |
1 |
Yes |
Resection |
No |
No |
Yes |
No |
24 |
No data |
Not reached |
Not reached |
[6] |
|
4 |
49 |
M |
1 |
Yes |
Biopsy |
No |
No |
No |
No |
18 |
PR |
Not reached |
Not reached |
[7] |
|
5 |
56 |
M |
1 |
Yes |
Biopsy |
No |
Yes |
No |
No |
2 |
PD |
2 |
Not reached |
[8] |
|
6 |
38 |
M |
1 |
Yes |
Resection |
No |
No |
Yes |
No |
21 |
No data |
No data |
Not reached |
[9] |
|
7 |
49 |
M |
1 |
Yes |
Biopsy |
No |
No |
Yes |
No |
18 |
No data |
No data |
Not reached |
[9] |
|
8 |
55 |
M |
1 |
Yes |
Resection |
No |
No |
Yes |
No |
42 |
No data |
No data |
Not reached |
[10] |
|
9 |
53 |
M |
1 |
Yes |
Biopsy |
CYCLO |
No |
No |
No |
3 |
PR |
Not reached |
Not reached |
[11] |
|
10 |
42 |
M |
1 |
No |
Resection |
No |
No |
No |
Yes |
24 |
CR |
Not reached |
Not reached |
[12] |
|
11 |
24 |
F |
1 |
No |
Lung biopsy |
No |
No |
No |
No |
12 |
CR |
Not reached |
Not reached |
[13] |
|
12 |
48 |
M |
1 or 2 |
No |
Lung biopsy |
No |
No |
No |
Yes |
18 |
PR |
Not reached |
Not reached |
[14] |
|
13 |
67 |
M |
2 |
Yes |
Resection |
MTX HD |
Yes |
No |
No |
12 |
CR |
Not reached |
Not reached |
[15] |
|
14 |
52 |
F |
2 |
Yes |
Biopsy |
CYCLO |
No |
No |
No |
24 |
No data |
No data |
Not reached |
[9] |
|
15 |
60 |
M |
2 |
Yes |
Biopsy |
No |
No |
Yes + Ifn |
No |
18 |
PR |
Not reached |
Not reached |
[16] |
|
16 |
42 |
F |
2 |
Yes |
Biopsy |
No |
No |
Yes |
No |
23 |
PR |
Not reached |
Not reached |
[16] |
|
17 |
22 |
M |
2 or 3 |
No |
Resection |
Yes |
Yes |
No |
No |
36 |
CR |
No data |
36 |
[5] |
|
18 |
36 |
F |
2 or 3 |
Yes |
Resection |
Yes |
Yes |
No |
No |
48 |
CR |
Not reached |
Not reached |
[5] |
|
19 |
73 |
F |
2 or 3 |
Yes |
Resection |
No |
No |
No |
No |
60 |
No data |
Not reached |
Not reached |
[6] |
|
20 |
80 |
F |
2 or 3 |
No |
Lung biopsy |
TMZ |
No |
No |
Yes |
2 |
PD |
No data |
2 |
[17] |
|
21 |
62 |
F |
3 |
Yes |
Biopsy |
No |
No |
Yes |
No |
29 |
PR |
Not reached |
Not reached |
[16] |
|
22 |
41 |
M |
3 |
No |
Lung biopsy |
MTX HD, MTX IT,
ARAC, ARAC IT, CE |
No |
No |
Yes |
18 |
PR |
Not reached |
Not reached |
[18] |
|
23 |
19 |
M |
3 |
No |
Lung biopsy |
CHOP |
Yes |
No |
No |
3 |
PD |
No data |
3 |
[19] |
|
24 |
38 |
F |
3 |
Yes |
Biopsy |
MTX IT, MTX HD |
Yes |
No |
No |
221 |
No data |
Not reached |
Not reached |
[9] |
|
25 |
74 |
F |
3 |
Yes |
Resection |
No |
No |
No |
No |
0.25 |
No data |
No data |
0.25 |
[20] |
Time to progression in months; Time to death in
months; F: Female; M: Male; CR: Complete
response; PR: Partial response; PD: Progressive disease, F/U: Follow up (in
months), RT: Radiotherapy; Chemotx: Chemotherapy; IT:
Intra thecal; Ritux: Rituximab; CEP: Cyclophosphamide etoposide
prednisone; MTX:
Methotrexate; HD: High dose; CVP: Rituximab cyclophosphamide vincristine
prednisone; TMZ: Temozolomide; CHOP: Cyclophosphamide adriamycin
vincristine prednisone; Cyclo: Cyclophosphamide; IFN:
Interferon α-2b; NR: Not reached.